Home > Riviste > Minerva Urologica e Nefrologica > Fascicoli precedenti > Minerva Urologica e Nefrologica 2017 June;69(3) > Minerva Urologica e Nefrologica 2017 June;69(3):242-52



Publication history
Per citare questo articolo


Rivista di Nefrologia e Urologia

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984




Minerva Urologica e Nefrologica 2017 June;69(3):242-52

DOI: 10.23736/S0393-2249.16.02815-0


lingua: Inglese

The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late?

Fabrizio PRESICCE 1, Cosimo DE NUNZIO 1, Mauro GACCI 2, Roman SOSNOWSKY 3, Riccardo LOMBARDO 1, Francesco PORPIGLIA 4, Andrea TUBARO 1

1 Department of Urology, Sant’Andrea Hospital, Sapienza University, Rome, Italy; 2 Department of Urology, Careggi Hospital, University of Florence, Florence, Italy; 3 Department of Uro-oncology, M. Sklodowska–Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland; 4 Division of Urology, Department of Oncology, University of Turin, Turin, Italy


INTRODUCTION: The aim of this article is to systematically collect the available evidence on the influence of lower urinary tract symptoms (LUTS) medical treatment on benign prostatic hyperplasia (BPH) surgery.
EVIDENCE ACQUISITION: A systematic literature search January 1990 until June 2016 was performed by combining the following MeSH terms: “lower urinary tract symptoms”, “benign prostatic hyperplasia”, “male”, “medical treatment”, “surgical treatment”, “deferred/postponed treatment/intervention”, “early intervention/treatment”. Each article title and abstract was reviewed for relevance and appropriateness with regards to the topic of this review.
EVIDENCE SYNTHESIS: The pharmacological treatment of LUTS is undoubtedly a successful story in the field of urology. Over the last two decades, the introduction of novel pharmaceutical agents has dramatically reduced the rate of BPH surgery interventions all over the world. Thus, nowadays, patients who undergo surgery are generally older, with more severe comorbidities and with larger prostates, theoretically requiring more challenging interventions. Nevertheless, the recent advances in surgical techniques and instruments have counterbalanced this unfavorable scenario and, overall, a non-pejorative trend has been observed in peri-/postoperative complications. On the other hand, evidence from the “pre-pharmacological-treatment era” suggested that immediate BPH surgery might be the best option for patients at risk of severe BPH progression. Still, no clear-cut, shared criteria have yet been established to effectively identify these patients.
CONCLUSIONS: Several questions remain unanswered regarding the role of medical treatment in BPH, and good-quality studies available on this topic are surprisingly rare. The evidence presented in this review supports the need for prospective comparative studies evaluating long-term LUTS/BPH pharmacological treatment versus an early surgical intervention, particularly using the emerging laser technologies.

KEY WORDS: Prostatic hyperplasia - Lower urinary tract symptoms - Urinary bladder neck obstruction - Operative surgical procedures - Postoperative complications

inizio pagina

Publication History

Issue published online: March 28, 2017
Article first published online: November 23, 2016

Per citare questo articolo

Presicce F, De Nunzio C, Gacci M, Sosnowsky R, Lombardo R, Porpiglia F, et al. The influence of the medical treatment of LUTS on benign prostatic hyperplasia surgery: do we operate too late? Minerva Urol Nefrol 2017;69:242-52. DOI: 10.23736/S0393-2249.16.02815-0

Corresponding author e-mail